000			01777ngm a2200397 a 4500
001			HST5267
003			UkLoHST
006			m c
007			cr|cna|||a||||
007			vz|czazum
008			210404s2021 enk|||||||||||s|||v|eng d
028	5	0	_a5267 _bHenry Stewart Talks
035			_a(UkLoHST)4547
040			_aUkLoHST _beng _cUkLoHST
100	1		_aLerchen, Hans-Georg, _u(Bayer AG, Germany) _4spk
245	1	0	_aDevelopment of antibody prodrug conjugates activated by legumain _h[electronic resource] / _cHans-Georg Lerchen.
260			_aLondon : _bHenry Stewart Talks, _c2021.
300			_a1 online resource (1 streaming video file (35 min.) : _bcolor, sound).
490	1		_aThe biomedical & life sciences collection, _x2056-452X
500			_aAnimated audio-visual presentation with synchronized narration.
500			_aTitle from title frames.
505	0		_aContents: Modular composition of antibody drug conjugates -- ADC mode of action -- TWEAK receptor as an ADC target -- Improvements to achieve stable antibody conjugation -- KSP inhibitors as ADC toxophores -- Legumain-cleavable antibody prodrug conjugates -- Conceptualization of Antibody Prodrug Conjugates (APDCs) to increase the therapeutic window.
506			_aAccess restricted to subscribers.
538			_aMode of access: World Wide Web.
650		0	_aAntibody-drug conjugates.
650		0	_aDrug development.
650		2	_aAntibodies, Monoclonal.
650		2	_aAntineoplastic Agents.
650		2	_aasparaginylendopeptidase.
650		2	_aCysteine Endopeptidases.
650		2	_aImmunoconjugates.
650		2	_aProdrugs.
650		2	_aTWEAK Receptor.
830		0	_aHenry Stewart talks. _pBiomedical & life sciences collection.
856	4	0	_uhttps://hstalks.com/bs/4547/
999			_c75806 _d75806